{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:23:41Z","timestamp":1792596221695,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/leu.2014.44","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T07:41:35Z","timestamp":1390462895000},"page":"1657-1665","source":"Crossref","is-referenced-by-count":189,"title":["BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies"],"prefix":"10.1038","volume":"28","author":[{"given":"J M","family":"Bogenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Pierceall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Lena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-X","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Mantei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I M","family":"Gonzales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Camoriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Fauble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Tiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y H","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K R","family":"Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D O","family":"Azorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"key":"BFleu201444_CR1","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.leukres.2012.08.026","volume":"36","author":"RA Mesa","year":"2012","unstructured":"Mesa RA, Tibes R . MPN blast phase: clinical challenge and assessing response. Leuk Res 2012; 36: 1496\u20131497.","journal-title":"Leuk Res"},{"key":"BFleu201444_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","volume":"36","author":"C Cherington","year":"2012","unstructured":"Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012; 36: 1147\u20131151.","journal-title":"Leuk Res"},{"key":"BFleu201444_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223\u2013232.","journal-title":"Lancet Oncol"},{"key":"BFleu201444_CR4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M Lubbert","year":"2011","unstructured":"Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987\u20131996.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR5","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","volume":"116","author":"S Thepot","year":"2010","unstructured":"Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010; 116: 3735\u20133742.","journal-title":"Blood"},{"key":"BFleu201444_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF . Multicenterphase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556\u2013561.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562\u2013569.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR8","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670\u20132677.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/leu.2008.136","volume":"23","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009; 23: 180\u2013182.","journal-title":"Leukemia"},{"key":"BFleu201444_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/leu.2012.312","volume":"27","author":"C Craddock","year":"2013","unstructured":"Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M et al. Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013; 27: 1028\u20131036.","journal-title":"Leukemia"},{"key":"BFleu201444_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18632\/oncotarget.481","volume":"3","author":"T Cluzeau","year":"2012","unstructured":"Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A et al. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 2012; 3: 490\u2013501.","journal-title":"Oncotarget"},{"key":"BFleu201444_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/leu.2011.71","volume":"25","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147\u20131152.","journal-title":"Leukemia"},{"key":"BFleu201444_CR13","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/leu.2012.152","volume":"26","author":"S Ettou","year":"2012","unstructured":"Ettou S, Audureau E, Humbrecht C, Benet B, Jammes H, Clozel T et al. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia 2012; 26: 2297\u20132299.","journal-title":"Leukemia"},{"key":"BFleu201444_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.1994.tb04904.x","volume":"87","author":"K Tohyama","year":"1994","unstructured":"Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y . Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol 1994; 87: 235\u2013242.","journal-title":"Br J Haematol"},{"key":"BFleu201444_CR15","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/blood-2011-07-367557","volume":"119","author":"R Tibes","year":"2012","unstructured":"Tibes R, Bogenberger JM, Chaudhuri L, Hagelstrom RT, Chow D, Buechel ME et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 2012; 119: 2863\u20132872.","journal-title":"Blood"},{"key":"BFleu201444_CR16","first-page":"173","volume":"110","author":"CP Reynolds","year":"2005","unstructured":"Reynolds CP, Maurer BJ . Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med 2005; 110: 173\u2013183.","journal-title":"Methods Mol Med"},{"key":"BFleu201444_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","volume":"113","author":"SM Kornblau","year":"2009","unstructured":"Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009; 113: 154\u2013164.","journal-title":"Blood"},{"key":"BFleu201444_CR18","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006; 5: 2512\u20132521.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201444_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1182\/blood-2012-02-409888","volume":"120","author":"BZ Carter","year":"2012","unstructured":"Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR et al. Survivin is highly expressed in CD34(+)38(-) leukemic stem\/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012; 120: 173\u2013180.","journal-title":"Blood"},{"key":"BFleu201444_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334: 1129\u20131133.","journal-title":"Science"},{"key":"BFleu201444_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151: 344\u2013355.","journal-title":"Cell"},{"key":"BFleu201444_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909\u2013916.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488\u2013496.","journal-title":"J Clin Oncol"},{"key":"BFleu201444_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149\u20131159.","journal-title":"Lancet Oncol"},{"key":"BFleu201444_CR25","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/jm800669s","volume":"51","author":"CM Park","year":"2008","unstructured":"Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008; 51: 6902\u20136915.","journal-title":"J Med Chem"},{"key":"BFleu201444_CR26","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421\u20133428.","journal-title":"Cancer Res"},{"key":"BFleu201444_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663\u20131674.","journal-title":"Blood"},{"key":"BFleu201444_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202\u2013208.","journal-title":"Nat Med"},{"key":"BFleu201444_CR29","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, ABT-199 Cory S . a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285\u20132288.","journal-title":"Blood"},{"key":"BFleu201444_CR30","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","volume":"115","author":"D Yecies","year":"2010","unstructured":"Yecies D, Carlson NE, Deng J, Letai A . Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304\u20133313.","journal-title":"Blood"},{"key":"BFleu201444_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389\u2013399.","journal-title":"Cancer Cell"},{"key":"BFleu201444_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJM199802263380902","volume":"338","author":"M Silva","year":"1998","unstructured":"Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernandez-Luna JL . Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998; 338: 564\u2013571.","journal-title":"N Engl J Med"},{"key":"BFleu201444_CR33","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2008-03-143321","volume":"113","author":"A Zeuner","year":"2009","unstructured":"Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A et al. Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 2009; 113: 1522\u20131525.","journal-title":"Blood"},{"issue":"Pt 3","key":"BFleu201444_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1042\/bj3360735","volume":"336","author":"W El-Assaad","year":"1998","unstructured":"El-Assaad W, El-Sabban M, Awaraji C, Abboushi N, D4baibo GS . Distinct sites of action of Bcl-2 and Bcl-xL in the ceramide pathway of apoptosis. Biochem J 1998; 336 (Pt 3): 735\u2013741.","journal-title":"Biochem J"},{"key":"BFleu201444_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","volume":"145","author":"F Edlich","year":"2011","unstructured":"Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011; 145: 104\u2013116.","journal-title":"Cell"},{"key":"BFleu201444_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393\u2013403.","journal-title":"Mol Cell"},{"key":"BFleu201444_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A . BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007; 12: 171\u2013185.","journal-title":"Cancer Cell"},{"key":"BFleu201444_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351\u2013365.","journal-title":"Cancer Cell"},{"key":"BFleu201444_CR39","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1182\/blood-2011-11-382226","volume":"119","author":"J Aimiuwu","year":"2012","unstructured":"Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012; 119: 5229\u20135238.","journal-title":"Blood"},{"key":"BFleu201444_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4161\/epi.5.3.11409","volume":"5","author":"VM Komashko","year":"2010","unstructured":"Komashko VM, Farnham PJ . 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010; 5: 229\u2013240.","journal-title":"Epigenetics"},{"key":"BFleu201444_CR41","doi-asserted-by":"crossref","unstructured":"Bogenberger JM, Shi C-X, Gonzales I, Tiedemann R, Noel P, Slack J et al. RNAi screening identifies BCL-XL as an erythroid lineage-specific 5-Azacytidine sensitizer while the BCL-2\/BCL-XL\/BCL-2 inhibitor ABT-737 results in more universal sensitization in leukemia cells. Blood (ASH Annual Meeting Abstracts) 2011; 118, Abstract 3513.","DOI":"10.1182\/blood.V118.21.3513.3513"},{"key":"BFleu201444_CR42","first-page":"128","volume":"70","author":"JM Bogenberger","year":"2010","unstructured":"Bogenberger JM, Shi C-X, Hagelstrom RT, Gonzales I, Choudhary A, Tiedemann R et al. Synthetic lethal RNAi screening identifies inhibition of Bcl-2 family members as sensitizing to 5-Azacytidine in myeloid cells. AACR (Annual Meeting Abstracts) 2010; 70, Abstract LB 128.","journal-title":"AACR (Annual Meeting Abstracts)"},{"key":"BFleu201444_CR43","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","volume":"91","author":"T Tsao","year":"2012","unstructured":"Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol 2012; 91: 1861\u20131870.","journal-title":"Ann Hematol"},{"key":"BFleu201444_CR44","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 2012; 18: 3163\u20133169.","journal-title":"Clin Cancer Res"},{"key":"BFleu201444_CR45","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1182\/blood-2011-03-340364","volume":"118","author":"S Al-Harbi","year":"2011","unstructured":"Al-Harbi S, Hill BT, Mazumder S, Singh K, Devecchio J, Choudhary G et al. An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 2011; 118: 3579\u20133590.","journal-title":"Blood"},{"key":"BFleu201444_CR46","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/cncr.26360","volume":"118","author":"K Kojima","year":"2012","unstructured":"Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M . Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 2012; 118: 1023\u20131031.","journal-title":"Cancer"},{"key":"BFleu201444_CR47","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1158\/1535-7163.MCT-07-0010","volume":"6","author":"T Kiziltepe","year":"2007","unstructured":"Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007; 6: 1718\u20131727.","journal-title":"Mol Cancer Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201444","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:04:59Z","timestamp":1684433099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFleu201444"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.44","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]}}}